U.K.'s Controversial NICE Suspends Publication Of Guidances Until After General Election
This article was originally published in The Pink Sheet Daily
Executive Summary
Its favorable recommendation of Alimta as maintenance therapy in lung cancer patients is the last before the U.K. election on May 6.
You may also be interested in...
NICE On Alimta, Pixuvri Ups Concerns It Prefers Cost Over Clinical Efficacy
NICE’s tentative nod to CTI’s Pixuvri for NHL and refusal to grant an indication extension to Lilly’s Alimta could spark industry concern that the agency favors lower cost over clinical effectiveness.
Price Discount Paves The Way For NICE To Clear GSK’s Revolade
U.K. drug cost watchdog NICE has cleared Glaxo’s Revolade and Alcon's Jetrea but rejected Lilly's Alimta as maintenance therapy in a subgroup of lung cancer patients.
NICE, In Final Decision, Rejects Roche's Tarceva For Lung Cancer Maintenance
The benefits of Roche's Tarceva as maintenance therapy for lung cancer are uncertain and the drug is not cost-effective, the U.K.'s cost regulator concludes in final guidance.